184:. This cell culture system is based on the "wells-in-a-well" concept and offers a far more complete experimental system than traditional isolated cell culture platforms, which use only one cell type. It consists of a testing plate with multiple, inner wells grouped within a surrounding chamber. Individual wells can be seeded with cell types from different organs. They are then covered and connected by an overlying medium, allowing well-to-well communication, while keeping the individual cell types separate. The IdMOC system is patented internationally.
881:
393:
889:
300:, Uzgare A., LaForge Y. (2012) Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: Results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen.
159:
After establishing IVAL, Li was the first to report successful cryopreservation of human hepatocytes to retain their viability, functions, and ability to be cultured (plateable cryopreserved human hepatocytes). Li and his researchers have developed numerous hepatocyte-based assays, including higher
120:
as a senior research toxicologist. He stayed with
Monsanto until 1993, eventually becoming senior fellow and head of two departments – Liver Biology and Pharmokinetics, Bioanalytics, and Radiochemistry. Other notable positions include director of the Surgical Research Institute of the
910:
400:
314:, Yang Q., Vermet H., Raoust N., Klieber S., and Fabre G. (2014) Evaluation of Human Hepatocytes Under Prolonged Culture in a Novel Medium for the Maintenance of Hepatic Differentiation: Results with the Model Pro-inflammatory Cytokine Interleukin 6.
980:
261:
Metabolism
Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin
35:. For the past three decades, Li has devoted his scientific career to the advancement of scientific concepts and technologies to accurately predict human drug properties. His research is focused on the development and application of human-based
939:
860:
839:
698:
407:
386:
379:
372:
918:
192:
Li has published over 160 research articles, book chapters, and reviews and co-edited 5 books in toxicology and drug-drug interactions. He is on the editorial board for various journals, including
81:
in 1969, he immigrated to the United States and in 1972 obtained a bachelor's degree in chemistry, with a minor in biology. He went on to complete a Ph.D. in biochemical sciences in 1976 at the
354:., Ryan P.M., Spolski R., Leonard W.J., Bourdi M., and Pohl, L.R. (2014) Thymic Stromal Lymphopoietin and Interleukin-4 Mediate the Pathogenesis of Drug-Induced Liver Injury in Mice.
128:
In addition to his work in the industry, Li has also taken on a variety of academic positions, including distinguished visiting professor at the
Institute of Chemical Carcinogenesis (
990:
985:
112:'s Cancer Research and Treatment Center (1977–1979). This was followed by a position as associate scientist and group leader in cellular and genetic toxicology with the
340:(2014) In vitro human hepatocyte-based experimental systems for early identification of drugs and drug candidates with adverse drug properties and biomarker discovery.
244:
Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.
975:
74:
965:
78:
1010:
1000:
133:
122:
125:
School of
Medicine (1993–1995) and chief scientific officer of In Vitro Technologies, Inc. (now owned by Celsis), Baltimore, Maryland (1998–2002).
995:
93:
137:
160:
throughput assays for P450 inhibition, time-dependent inhibition, P450 induction, cytokine suppression of ADME gene expression, and
815:
149:
970:
86:
129:
563:
538:
513:
488:
463:
434:
290:
and Doshi U. (2011) Higher
Throughput Screening Assays for Time-Dependent Inhibition of CYP3A4 in Human Hepatocytes.
767:
104:
Li has held a variety of research and teaching positions throughout the biomedical field. After graduating from the
644:
Li, Albert P. (2007-05-20). "Human hepatocytes: isolation, cryopreservation and applications in drug development".
743:
719:
276:
and Doshi U. (2011) Higher
Throughput Screening Assays for CYP3A4 Inhibition and Induction in Human Hepatocytes.
588:
109:
105:
82:
1005:
347:
Proctor W.R., Chakraborty M., Korrapati M.C., Morrison J.C., Berkson J.D., Semple K., Chea L.S., Yang Q.,
156:
testing, IVAL provides products and services to pharmaceutical development laboratories across the globe.
232:(2008) In vitro evaluation of metabolic drug-drug interactions: concepts and practice. In A.P. Li (Ed.),
28:
653:
20:
677:
669:
77:, where he excelled, particularly in the sciences. After being awarded a scholarship from the
661:
42:
148:
In 2004, Li founded In Vitro ADMET Laboratories (IVAL), a product supplier and preclinical
50:
41:
experimental systems in drug discovery and development. He is a pioneer in the isolation,
657:
791:
959:
816:"Cell Biology and Toxicology – incl. option to publish open access (Editorial Board)"
327:(2012) Editorial: metabolism and drug-drug interaction potential of biotherapeutics.
32:
46:
260:
243:
172:
In 2007, Li patented the
Integrated Discrete Multiple Organ Co-Culture system (
665:
673:
567:
542:
517:
492:
467:
442:
70:
681:
108:, Li took up a post as a research scientist and assistant professor at the
222:(2005) Preclininical in vitro screening assays for drug-like properties.
117:
58:
37:
24:
392:
Cell
Culture Tool and Method: The People's Republic of China Patent No.
981:
University of
Wisconsin–Madison College of Letters and Science alumni
862:
United States Patent: 6858146 – Artificial liver apparatus and method
621:"Hepatocytes, Media, Contract Research | In Vitro ADMET Laboratories"
596:
173:
54:
700:
United States Patent: 7186548 – Cell culture tool and method
19:
is president and CEO of In Vitro ADMET Laboratories (IVAL),
841:
United States Patent: 5270192 – Biological artificial liver
620:
410:; filed Sept 10, 2013; allowed and published March 12, 2015
375:; filed 02/07/92; allowable June 1993, published Dec. 1993.
792:"Editorial Board: The Journal of Toxicological Sciences"
114:
Lovelace
Biomedical and Environmental Research Institute
113:
941:
United States Patent: 9078430 – Cell preparation method
378:
Artificial liver apparatus and method: U.S. Patent No.
382:; filed 02/20/02; allowed and published Feb. 22, 2005.
132:), adjunct professor of pharmacology and physiology (
234:
Drug-drug Interactions in Pharmaceutical Development
136:), and affiliate professor of chemical engineering (
744:"Editorial Board ::: Drug Metabolism Letters"
720:"Editorial Board ::: Current Drug Metabolism"
615:
613:
768:"Chemico-Biological Interactions Editorial Board"
564:"In Vitro ADMET Laboratories, LLC | Meet Our CEO"
539:"In Vitro ADMET Laboratories, LLC | Meet Our CEO"
514:"In Vitro ADMET Laboratories, LLC | Meet Our CEO"
489:"In Vitro ADMET Laboratories, LLC | Meet Our CEO"
464:"In Vitro ADMET Laboratories, LLC | Meet Our CEO"
385:Cell Culture Tool and Method: U.S. Patent No. US
886:State Intellectual Property Office of the P.R.C
399:Cell Culture Tool and Method: Japan Patent No.
371:Biological Artificial Liver: U.S. Patent No.
8:
991:University of Maryland, College Park alumni
85:, working with the Biology Division of the
49:and their application in the evaluation of
986:Washington University in St. Louis faculty
75:St. Francis Xavier's College, Tai Kok Tsui
406:Cell Preparation Method: U.S. Patent No.
134:Saint Louis University School of Medicine
236:(1–30). New Jersey: John Wiley and Sons.
92:Li also holds an executive MBA from the
419:
116:(1979–1982). From there, Li joined the
915:Japan Platform for Patent Information
693:
691:
7:
976:St. Francis Xavier University alumni
429:
427:
425:
423:
94:University of Maryland, College Park
966:American people of Chinese descent
389:B2; Date of Patent: March 6, 2007.
138:Washington University in St. Louis
14:
206:Journal of Toxicological Sciences
69:Albert Li was born and raised in
1011:21st-century American biologists
1001:University of New Mexico faculty
593:In Vitro ADMET Laboratories, LLC
439:In Vitro ADMET Laboratories, LLC
367:Li currently holds six patents:
646:Chemico-Biological Interactions
396:; Date of Patent: May 26, 2010.
202:Chemico-Biological Interactions
996:University of Tennessee alumni
882:"Cell Culture Tool and Method"
215:Notable publications include:
150:contract research organization
1:
911:"Japanese Patent No. 4609799"
87:Oak Ridge National Laboratory
566:. 2015-11-25. Archived from
541:. 2015-11-25. Archived from
516:. 2015-11-25. Archived from
491:. 2015-11-25. Archived from
466:. 2015-11-25. Archived from
403:; allowed in September 2010.
210:Toxicology and Cell Biology
180:multiple-organ interaction
1027:
666:10.1016/j.cbi.2007.01.001
292:Drug Metabolism Letters 5
130:Guangzhou Medical College
45:, and culturing of human
176:), a method that models
110:University of New Mexico
65:Early life and education
329:Current Drug Metabolism
316:Drug Metabolism Letters
198:Drug Metabolism Letters
194:Current Drug Metabolism
106:University of Tennessee
83:University of Tennessee
79:University of Wisconsin
55:drug-drug interactions
971:Hong Kong scientists
302:Chem. Biol. Interact
224:Drug Discovery Today
123:St. Louis University
658:2007CBI...168...16L
265:Chem Biol Interact.
748:benthamscience.com
724:benthamscience.com
152:. Specializing in
278:J. Biomol. Screen
247:Drug Metab Dispos
1018:
951:
950:
949:
948:
936:
930:
929:
927:
926:
917:. Archived from
907:
901:
900:
898:
897:
888:. Archived from
878:
872:
871:
870:
869:
857:
851:
850:
849:
848:
836:
830:
829:
827:
826:
812:
806:
805:
803:
802:
788:
782:
781:
779:
778:
764:
758:
757:
755:
754:
740:
734:
733:
731:
730:
716:
710:
709:
708:
707:
695:
686:
685:
641:
635:
634:
632:
631:
625:invitroadmet.com
617:
608:
607:
605:
604:
595:. Archived from
585:
579:
578:
576:
575:
560:
554:
553:
551:
550:
535:
529:
528:
526:
525:
510:
504:
503:
501:
500:
485:
479:
478:
476:
475:
460:
454:
453:
451:
450:
441:. Archived from
431:
294:(3), 183-191(9).
164:hepatotoxicity.
118:Monsanto Company
43:cryopreservation
1026:
1025:
1021:
1020:
1019:
1017:
1016:
1015:
956:
955:
954:
946:
944:
938:
937:
933:
924:
922:
909:
908:
904:
895:
893:
880:
879:
875:
867:
865:
859:
858:
854:
846:
844:
838:
837:
833:
824:
822:
814:
813:
809:
800:
798:
796:www.jtoxsci.org
790:
789:
785:
776:
774:
766:
765:
761:
752:
750:
742:
741:
737:
728:
726:
718:
717:
713:
705:
703:
697:
696:
689:
643:
642:
638:
629:
627:
619:
618:
611:
602:
600:
587:
586:
582:
573:
571:
562:
561:
557:
548:
546:
537:
536:
532:
523:
521:
512:
511:
507:
498:
496:
487:
486:
482:
473:
471:
462:
461:
457:
448:
446:
433:
432:
421:
417:
365:
190:
170:
146:
102:
67:
51:drug metabolism
12:
11:
5:
1024:
1022:
1014:
1013:
1008:
1003:
998:
993:
988:
983:
978:
973:
968:
958:
957:
953:
952:
931:
902:
873:
852:
831:
807:
783:
759:
735:
711:
687:
636:
609:
580:
555:
530:
505:
480:
455:
435:"Meet Our CEO"
418:
416:
413:
412:
411:
404:
397:
390:
383:
376:
364:
361:
360:
359:
358:60, 1741–1752.
345:
342:Biomarkers Med
335:
322:
309:
295:
285:
271:
254:
237:
227:
189:
186:
169:
166:
145:
142:
101:
98:
73:. He attended
66:
63:
13:
10:
9:
6:
4:
3:
2:
1023:
1012:
1009:
1007:
1006:Living people
1004:
1002:
999:
997:
994:
992:
989:
987:
984:
982:
979:
977:
974:
972:
969:
967:
964:
963:
961:
943:
942:
935:
932:
921:on 2018-09-30
920:
916:
912:
906:
903:
892:on 2018-09-30
891:
887:
883:
877:
874:
864:
863:
856:
853:
843:
842:
835:
832:
821:
817:
811:
808:
797:
793:
787:
784:
773:
769:
763:
760:
749:
745:
739:
736:
725:
721:
715:
712:
702:
701:
694:
692:
688:
683:
679:
675:
671:
667:
663:
659:
655:
651:
647:
640:
637:
626:
622:
616:
614:
610:
599:on 2015-11-25
598:
594:
590:
584:
581:
570:on 2015-11-25
569:
565:
559:
556:
545:on 2015-11-25
544:
540:
534:
531:
520:on 2015-11-25
519:
515:
509:
506:
495:on 2015-11-25
494:
490:
484:
481:
470:on 2015-11-25
469:
465:
459:
456:
445:on 2015-11-25
444:
440:
436:
430:
428:
426:
424:
420:
414:
409:
405:
402:
398:
395:
391:
388:
384:
381:
377:
374:
370:
369:
368:
362:
357:
353:
350:
346:
343:
339:
336:
333:
330:
326:
323:
320:
317:
313:
310:
307:
303:
299:
296:
293:
289:
286:
284:(8), 903–909.
283:
279:
275:
272:
269:
266:
263:
258:
255:
253:(8),1598-603.
252:
248:
245:
241:
238:
235:
231:
228:
225:
221:
218:
217:
216:
213:
211:
207:
203:
199:
195:
187:
185:
183:
179:
175:
167:
165:
163:
157:
155:
151:
143:
141:
139:
135:
131:
126:
124:
119:
115:
111:
107:
99:
97:
95:
90:
88:
84:
80:
76:
72:
64:
62:
60:
56:
52:
48:
44:
40:
39:
34:
33:Massachusetts
30:
26:
22:
18:
945:, retrieved
940:
934:
923:. Retrieved
919:the original
914:
905:
894:. Retrieved
890:the original
885:
876:
866:, retrieved
861:
855:
845:, retrieved
840:
834:
823:. Retrieved
820:springer.com
819:
810:
799:. Retrieved
795:
786:
775:. Retrieved
771:
762:
751:. Retrieved
747:
738:
727:. Retrieved
723:
714:
704:, retrieved
699:
652:(1): 16–29.
649:
645:
639:
628:. Retrieved
624:
601:. Retrieved
597:the original
592:
589:"About IVAL"
583:
572:. Retrieved
568:the original
558:
547:. Retrieved
543:the original
533:
522:. Retrieved
518:the original
508:
497:. Retrieved
493:the original
483:
472:. Retrieved
468:the original
458:
447:. Retrieved
443:the original
438:
366:
355:
351:
348:
341:
337:
331:
328:
324:
318:
315:
311:
305:
301:
297:
291:
287:
281:
277:
273:
267:
264:
256:
250:
246:
239:
233:
229:
223:
219:
214:
209:
205:
201:
197:
193:
191:
188:Publications
181:
177:
171:
161:
158:
153:
147:
127:
103:
91:
68:
36:
17:Albert P. Li
16:
15:
321:(1), 12–18.
226:2, 179–195.
57:, and drug
47:hepatocytes
960:Categories
947:2015-09-22
925:2015-09-22
896:2015-09-22
868:2015-09-22
847:2015-09-22
825:2015-09-23
801:2015-09-23
777:2015-09-23
753:2015-09-23
729:2015-09-23
706:2015-09-22
630:2015-10-08
603:2015-10-08
574:2022-09-21
549:2022-09-21
524:2022-09-21
499:2022-09-21
474:2022-09-21
449:2015-10-08
415:References
356:Hepatology
344:. 8, 1–11.
674:0009-2797
408:9,078,430
387:7,186,548
380:6,858,146
373:5,270,192
338:Li, A. P.
325:Li, A. P.
298:Li, A. P.
288:Li, A. P.
274:Li, A. P.
270:(1), 4–8.
257:Li, A. P.
240:Li, A. P.
230:Li, A. P.
71:Hong Kong
772:Elsevier
682:17270162
312:Li, A.P.
220:Li A. P.
182:in vitro
162:in vitro
154:in vitro
96:(2002).
59:toxicity
38:in vitro
25:Maryland
21:Columbia
654:Bibcode
401:4609799
363:Patents
259:(2009)
242:(2009)
178:in vivo
680:
672:
394:626030
334:, 881.
308:(1–8).
208:, and
100:Career
29:Malden
27:, and
174:IdMOC
168:IdMOC
678:PMID
670:ISSN
306:199,
144:IVAL
662:doi
650:168
352:A.P
268:179
262:B1.
140:).
962::
913:.
884:.
818:.
794:.
770:.
746:.
722:.
690:^
676:.
668:.
660:.
648:.
623:.
612:^
591:.
437:.
422:^
349:Li
332:13
304:.
282:16
280:.
251:37
249:.
212:.
204:,
200:,
196:,
89:.
61:.
53:,
31:,
23:,
928:.
899:.
828:.
804:.
780:.
756:.
732:.
684:.
664::
656::
633:.
606:.
577:.
552:.
527:.
502:.
477:.
452:.
319:8
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.